Clinical Phase 2 study data for the treatment of child growth hormone deficiency published by Novo nornod

recently, Novo Nordisk released clinical Phase 2 study data for the treatment of childhood growth hormone deficiency, showing that it has the same effect as thecompany's(
-day drug(® (®, growth hormone)a long-lasting analogue of SomapacitanSomapacitan, a long-acting hormone in the human body, and clinical studies are currently under way for the treatment of growth hormone deficiencySomapacitan is based on nearly 20 years of long-acting protein technology that has been used in insulin, GLP-1 and today's growth hormonesBy modifying natural growth hormone to increase its binding to plasma albumin, Somapacitan is suitable for weekly administrationData from Somapacitan's REAL 3 study were presented at the 57th annual meeting of the European Society of Paediatric EndocrinologyREAL 3 is a multi-country, randomized, parallel group, drug-controlledtrial(the main endpoint of the study was to evaluate the effect of multiple doses once a week compared to the treatment of 59 pre-adolescent children with growth hormone deficiency in Norditropin once a day)Clinical participants were assigned random treatment for somapacitan (0.04, 0.08, 0.16 mg/kg/week) or Norditropin (0.034 mg/kg/day)results showed no statistically significant difference in the annual height rate of children receiving 0.08 and 0.16 (mg/kg/week) dose levels compared to NorditropinThe average annual height speed of the three dose levels of the drug was 8.0 cm, 10.9 cm and 12.9 cm, while the average annual height speed of Norditropin was 11.4 cmsomapacitan is well tolerated in all clinical doses, with no clinically-related safety or local tolerance problems Norditropin Norditropin is a drug containing growth hormone, in which a naturally occurring copy of human growth hormone is produced by "recombinant DNA technology." Growth hormone promotes growth in childhood and adolescence and also affects the way the body processes proteins, fats and carbohydrates Sold in EU member states under norditropin FlexPro, Norditropin Nordi Flex, Norditropin SimpleXx and related names currently used as an alternative therapy for endogenous growth hormone (GH) deficiency in children and adults 　　Norditropin is also used for growth failures caused by Noonan syndrome, Turner syndrome, small fetal age (SGA), short stature (ISS), and Prader-Willi syndrome (PWS)